 MARLBOROUGH, Mass., March 25, 2021 PRNewswire -- Phio Pharmaceuticals Corp. Nasdaq: PHIO, a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi INTASYLTM therapeutic platform, today reported its financial results for the year ended December 31, 2020 and provided a business update. 